Literature DB >> 7519045

Molecular analysis of simple variant translocations in acute promyelocytic leukemia.

J Borrow1, J Shipley, K Howe, F Kiely, A Goddard, D Sheer, A Srivastava, A C Antony, T Fioretos, F Mitelman.   

Abstract

The primary cytogenetic abnormality in acute promyelocytic leukemia (APL; FAB M3) is a reciprocal translocation, t(15;17)(q22;q12), which serves to fuse the PML gene on chromosome 15 to the retinoic acid receptor alpha (RARA) gene on chromosome 17. A PML-RARA fusion message transcribed from the der(15) is thought to mediate leukemogenesis. Two APL patients with simple variants of this translocation, t(3;15)(q21;q22) and t(X;15)(p11;q22), have previously been reported who lack cytogenetic involvement of chromosome 17, although their breakpoint positions on chromosome 15 still suggest the involvement of the PML gene. Here we report on a combined analysis by molecular genetics and in situ hybridization of these two patients, in which we wanted to determine whether the PML gene has alternative fusion partners or whether cryptic rearrangement of the RARA locus has occurred instead. A cryptic involvement of RARA was demonstrated in both patients by a combination of Southern analysis, reverse transcription coupled to PCR (RT-PCR), and fluorescence in situ hybridization. The results indicate an absolute requirement for the rearrangement of the RARA gene in the pathogenesis of APL and underline the importance of RARA during normal myeloid differentiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519045     DOI: 10.1002/gcc.2870090403

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  1 in total

1.  Interphase fluorescence in situ hybridization and reverse transcription polymerase chain reaction as a diagnostic aid for synovial sarcoma.

Authors:  J Shipley; J Crew; S Birdsall; S Gill; J Clark; C Fisher; A Kelsey; T Nojima; H Sonobe; C Cooper; B Gusterson
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.